Study of Panzyga to prevent infections in people with weak immune systems
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial tests if a medication called Panzyga can help prevent infections in people with autoimmune conditions who have low antibody levels after B-cell therapy. It may be an option if you have a condition like multiple sclerosis, rheumatoid arthritis, or lupus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have an autoimmune condition like multiple sclerosis, rheumatoid arthritis, lupus, or similar.
- You must have taken a B-cell depleting therapy (like Rituxan) within the last 3 months and be planning to continue it.
- Your IgG (antibody) levels must be low, specifically below 500 mg/dL.
- You must be willing to use effective birth control during the study and for 30 days after treatment.
- You cannot have had a severe allergic reaction to immunoglobulin or blood products in the past.
- You must not have a current serious infection or have had more than one serious infection in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medicine called IgPro20 can help prevent infections in people with multiple myeloma who have low antibody levels and are being treated with a bispecific antibody. If you have relapsed or refractory myeloma and have recently started a bispecific antibody, this study might help protect you from getting serious infections.
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
This Phase 3 study compares different dose schedules of PANZYGA (immune-globulin) in children with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It aims to find a dosing plan that is both safe and effective for improving symptoms and function.
This trial studies whether IVIG (an immune therapy made from donated antibodies) can reduce pain from autoimmune small fiber neuropathy. You may be a candidate if your tests show certain autoantibodies (TS-HDS, FGFR3, or Plexin-D1) and your symptom scores are high enough.
This trial tests a new intravenous immunoglobulin (IVIG) treatment for patients with primary immunodeficiency diseases, such as common variable immune deficiency (CVID) or X-linked agammaglobulinemia (XLA). It aims to see if this medicine is safe and works well to prevent infections.
Hear when a new Hypogammaglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.